Enanta Pharmaceuticals | Passivo Circulante





Passivo Circulante Alterar Data
AbbVie USD 39.39B 376M 2025-09
Amgen USD 25.49B 3.7B 2025-12
Anika Therapeutics USD 19.09M 3.01M 2025-09
Arrowhead Research USD 347.42M 151.94M 2025-12
AstraZeneca USD 34.05B 518M 2025-09
BioCryst Pharmaceuticals USD 190.24M 13.08M 2025-09
Biogen USD 3.35B 59.4M 2025-12
Bristol-Myers Squibb USD 28.14B 608M 2025-09
Enanta Pharmaceuticals USD 48.56M 4.01M 2025-09
Gilead Sciences USD 12.3B 1.11B 2025-09
GlaxoSmithKline GBP 21.39B 57M 2025-12
Halozyme Therapeutics USD 837.23M 702.95M 2025-09
Heron Therapeutics USD 89.71M 168.89M 2025-09
Immunic USD 30.08M 2.77M 2025-09
Incyte USD 1.52B 176.44M 2025-12
Insmed USD 417.21M 105.53M 2025-09
Ionis Pharmaceuticals USD 903.46M 6.22M 2025-09
J&J USD 50.87B 3.31B 2025-09
Karyopharm Therapeutics USD 87.16M 12.06M 2025-09
Ligand Pharmaceuticals USD 30.54M 34.2M 2025-09
Merck USD 28.63B 2.59B 2025-09
Neurocrine Biosciences USD 638M 91.7M 2025-09
Novartis USD 32B 286M 2025-09
Novavax USD 429.87M 40.73M 2025-09
Pfizer USD 36.6B 1.13B 2025-09
PTC Therapeutics USD 866.24M 238.44M 2025-09
Roche Holding CHF 28B 421M 2025-12
Sarepta Therapeutics USD 921.42M 1.48M 2025-09
Vertex Pharmaceuticals USD 4.48B 336.9M 2025-09


Enanta Pharmaceuticals Passivo Circulante - Valores atuais, dados históricos, previsões, estatísticas, gráficos e calendário econômico - Feb 2026.